Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-5778Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Bostel, Tilman | - |
| dc.contributor.author | Mattke, Matthias | - |
| dc.contributor.author | Nicolay, Nils Henrik | - |
| dc.contributor.author | Welzel, Thomas | - |
| dc.contributor.author | Wollschläger, Daniel | - |
| dc.contributor.author | Akbaba, Sati | - |
| dc.contributor.author | Mayer, Arnulf | - |
| dc.contributor.author | Sprave, Tanja | - |
| dc.contributor.author | Debus, Jürgen | - |
| dc.contributor.author | Uhl, Matthias | - |
| dc.date.accessioned | 2021-04-23T08:59:17Z | - |
| dc.date.available | 2021-04-23T08:59:17Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/5787 | - |
| dc.description.abstract | BACKGROUND This study aimed to analyze the oncological long-term results and late toxicity of carbon ion-based radiotherapy (RT) of patients with sacral chordoma and to identify potential prognostic factors for local control (LC) and overall survival (OS). METHODS A total of 68 patients with sacral chordoma treated at the Heidelberg Ion Beam Therapy Center were included in this study. Of these 52 patients (77%) received a primary RT and 16 patients (23%) received a RT in a recurrent situation. All patients were treated with carbon ion RT (CIRT), either in combination with photons (n = 22; 32%) or as a monotherapy (n = 46; 68%), with a median radiation dose of 66 Gy RBE (range 60–74 Gy). In 40 patients (59%), RT was performed in the postoperative situation. Postoperative care included regular MRI scans. Local progression was defined as an enlargement of the maximum tumor diameter by 10% or a new tumor growth within the planning target volume (PTV). LC and OS were determined using the Kaplan-Meier method. Furthermore, the relevance of various prognostic factors for LC and OS was assessed by univariate and multivariate analysis. RESULTS The median follow-up period was 60 months (range 1.3–97.4 months). The 5-year rates for LC, progression-free survival, metastasis-free survival and OS were 53, 53, 52 and 74%, respectively. Local recurrence was observed in 31 patients (46%), occurring after a median follow-up time of 25 months (range 2.5–73.1 months). Only 10% of local recurrences occurred later than 5 years after RT. Statistical analysis showed that RT in the relapse situation corresponded to inferior LC rates compared to the primary situation, while other factors such as the GTV, radiation dose (EQD2) and treatment approach (CIRT alone vs. CIRT combined with photons) were insignificant. For OS after RT, patient age and PTV size proved to be significant predictors. The incidence of late toxicity ≥ III° according to CTCAE v5.0 was 21%. Sacral insufficiency fractures occurred in 49% of patients (maximum III°: 16%) and were thus by far the most frequent late side effect in our analysis. Radiogenic damage to the peripheral nerves, intestinal tract and skin was observed in only 9% (≥ III°: 5%), 3% (all II°) and 9% (all I°) of patients. CONCLUSION Our analysis showed only moderate long-term LC rates after carbon ion-based RT, with sacral chordomas having a particularly poor prognosis in the recurrent situation. Therefore, future studies should evaluate the safety and effectiveness of further dose escalation and hypofractionation of RT in sacral chordoma and weight potential benefits of dose escalation against side effects. | en_GB |
| dc.language.iso | eng | de |
| dc.rights | CC BY | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.ddc | 610 Medizin | de_DE |
| dc.subject.ddc | 610 Medical sciences | en_GB |
| dc.title | High-dose carbon-ion based radiotherapy of primary and recurrent sacrococcygeal chordomas : long-term clinical results of a single particle therapy center | en_GB |
| dc.type | Zeitschriftenaufsatz | de |
| dc.identifier.doi | http://doi.org/10.25358/openscience-5778 | - |
| jgu.type.dinitype | article | en_GB |
| jgu.type.version | Published version | de |
| jgu.type.resource | Text | de |
| jgu.organisation.department | FB 04 Medizin | de |
| jgu.organisation.number | 2700 | - |
| jgu.organisation.name | Johannes Gutenberg-Universität Mainz | - |
| jgu.rights.accessrights | openAccess | - |
| jgu.journal.title | Radiation oncology | de |
| jgu.journal.volume | 15 | de |
| jgu.pages.alternative | 206 | de |
| jgu.publisher.year | 2020 | - |
| jgu.publisher.name | BioMed Central | de |
| jgu.publisher.place | London | de |
| jgu.publisher.uri | https://doi.org/10.1186/s13014-020-01647-8 | de |
| jgu.publisher.issn | 1748-717X | de |
| jgu.organisation.place | Mainz | - |
| jgu.subject.ddccode | 610 | de |
| jgu.publisher.doi | 10.1186/s13014-020-01647-8 | - |
| jgu.organisation.ror | https://ror.org/023b0x485 | - |
| Appears in collections: | JGU-Publikationen | |
Files in This Item:
| File | Description | Size | Format | ||
|---|---|---|---|---|---|
 | bostel_tilman-high-dose_carb-20210420122108423.pdf | 2.51 MB | Adobe PDF | View/Open |